Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Novo Nordisk A/S (NVO)

56.94   0.25 (0.44%) 12-10 16:02
Open: 56.9 Pre. Close: 56.69
High: 57.13 Low: 56.72
Volume: 851,701 Market Cap: 134553M
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 57.157 - 57.502 57.502 - 57.833
Low: 55.894 - 56.305 56.305 - 56.699
Close: 56.314 - 56.916 56.916 - 57.492

Technical analysis

as of: 2019-12-10 4:33:00 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 67.76     One year: 79.14
Support: Support1: 55.34    Support2: 53.69
Resistance: Resistance1: 58.01    Resistance2: 67.76
Pivot: 56.16
Moving Average: MA(5): 56.96     MA(20): 56.47
MA(100): 52.79     MA(250): 50.52
MACD: MACD(12,26): 0.48     Signal(9): 0.52
Stochastic oscillator: %K(14,3): 79.72     %D(3): 78.87
RSI: RSI(14): 57.38
52-week: High: 58.01  Low: 43.60  Change(%): 23.8
Average Vol(K): 3-Month: 142286  10-Days: 129419

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
NVO has closed below upper band by 30.3%. Bollinger Bands are 5.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2019-12-04
Biocon sees a sweet spot with its affordable insulin in US
BENGALURU: Biocon is planning to take its recombinant human (rh) insulin into the US market soon and has tabled an affordable price range for the diabetes drug to the US administration, the top executive of its subsidiary Biocon Biologics said.“If you look at rh-insulin, I think it’s very interesting currently to look at the United States…We are heavily focusing on policy work, how can we work with key stakeholders in an administration, or with the FDA (US Food and Drug Administration) and having a dialogue to show options,” Christiane Hamacher told ET.The Bengaluru-headquartered biotech firm is planning to provide rh-insulin to middle- and lowincome countries at less than 10 cents a day.It has also charted an affordable price point for the US, the third largest country with a diabetic population, which analysts have flagged as a crisis.Biocon Biologics is chasing a revenue target of $1 billion in financial year 2021-22. In the previous fiscal year, its revenue had topped $200 million.Biocon has launched two biosimilars in the US market – pegfilgrastim and trastuzumab for cancer treatment – with partner Mylan.Currently, rh-insulin prices are significantly higher and not covered under health insurance.

2019-11-28
Global Diabetes Care (Insulin, OAD & GLP-1) Market 2019-2023 - Key Players are Novo Nordisk, Sanofi, and Eli Lilly
DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Global Diabetes Care Market (Insulin, OAD & GLP-1): Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Diabetic population is growing considerably all over the world. AAMEO region is experiencing…

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 2350.00
Shares Float (M) 1680.00
% Held by Insiders 0.02
% Held by Institutions 9.41
Shares Short (K) 7190
Shares Short P. Month (K)

Stock Financials

EPS 2.460
Book Value (p.s.) 3.080
PEG Ratio 2.48
Profit Margin 32.46
Operating Margin
Return on Assets (ttm) 28.3
Return on Equity (ttm) 77.1
Qtrly Rev. Growth 9.1
Gross Profit (p.s.) 40.089
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth 12.80
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E 23.15
P/E Growth Ratio
P/BV 18.49
P/S
P/CF

Dividends & Splits

Dividend 1.230
Dividend Yield 0.02
Dividend Pay Date 2019-08-27
Ex-Dividend Date 2019-03-22
Forward Dividend 1.250
Last Split Date 2014-01-09
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.